Lowest Cost Pembrolizumab: Unbeatable Offers & Insights | Khowai| Tripura| India
Drug Category
Immunotherapy
Drug name
Pembrolizumab
Complete Drug Name
Pembrolizumab Injection
Mode of Delivery
Injection
Brand
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Dosage/Dose
Pembrolizumab Dosage: 200 mg IV infusion every 3 weeks
Types of Cancer & Indication
Pembrolizumab serves as an authorized therapy for multiple cancer types, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, stomach and esophageal cancers, as well as tumors exhibiting microsatellite instability or defective mismatch repair. By enhancing the immune system's capacity, this drug efficiently targets and eradicates tumor development.
Mechanism of Action
Pembrolizumab, a groundbreaking immunotherapy intervention, amplifies the patient's immune prowess to detect and eliminate cancerous cells. It outsmarts cancer by impeding the exploitation of the PD-1 protein, which promotes immunity circumvention, ultimately fortifying the immune system. Showcasing remarkable versatility, pembrolizumab adeptly tackles various cancer manifestations, ushering a new era in personalized oncology therapy options.
Mechanism of Resistance
Pembrolizumab resistance arises when malignant cells undergo structural modifications that hinder immune checkpoint inhibition and obstruct T-cell interaction. As a result, cancer antigen presentation declines and inhibitory elements intensify, ultimately reducing pembrolizumab's strength and compromising its battle capabilities against cancerous expansion.
Side Effects
The use of Pembrolizumab injection can result in various undesired consequences, encompassing relentless fatigue, unending coughs, queasiness, and aggravated skin conditions. In specific instances, this therapeutic formulation may provoke severe repercussions like self-destructive organ assaults, lung inflammation, hepatic complications, or substantial infusion-associated troubles. Diligent monitoring becomes vital in quickly recognizing and addressing these plausible concerns.
Combination Therapy
In treating diverse cancer types, Pembrolizumab demonstrates remarkable efficacy when combined with specific medications depending on the cancer category. For non-squamous non-small cell lung cancer (NSCLC), a common approach is to mix pembrolizumab with pemetrexed and platinum-based chemotherapeutic agents such as cisplatin or carboplatin. Furthermore, the FDA authorizes the concurrent use of pembrolizumab and axitinib in addressing advanced renal cell carcinoma (RCC). Consultation with a medical expert is essential in personalizing optimal treatment strategies.
Final Cost
Avg. Pembrolizumab Injection cost: ₹70,000 in India. The above price is specific for Khowai, Tripura, India